State Selects Affinia Healthcare for ‘Outbreak’ Medication for St. Louis Region
Affinia Healthcare has been granted exclusive possession of Immunoglobulin antibody from the Missouri Department of Health and Human Services.
In the event of a Hepatitis A or measles outbreak, Affinia Healthcare will be responsible for the distribution of Immunoglobulin (IG) needed for the public response.
The Missouri Department of Health and Senior Services selected Affinia Healthcare to order, store, transfer and administration of the IG to other federally qualified health centers (FQHC) in the St. Louis region. Affinia Healthcare is one of five FQHCs in the state to be selected for this important project.
This IG product is produced under the name GamaSTAN, and is available from the company Grifols. This medication is used to provide protection (antibodies) against certain virus infections (hepatitis A, measles, chickenpox, rubella) in people who have not been vaccinated or have not had the infection before. It is also used to strengthen the body’s natural defense system (immune system) to lower the risk of infection in persons with a certain immune system problem (immunoglobulin deficiency).
“The medical community has seen a steady increase in the numbers of cases of Hepatitis A and measles, so it is wise to prepare for the worst-case scenario,” said Dr. Kendra Holmes, President & CEO for Affinia Healthcare. “The trust the state has placed in us is humbling yet speaks to the quality of care we provide on a daily basis as well as the level of expertise of our staff. We take this responsibility extremely serious.”